|
시장보고서
상품코드
2055026
세포 면역 치료 시장 : 치료법별, 유래별, 적응증별, 제조 방법별, 최종사용자별, 지역별Cellular Immunotherapy Market, By Therapy Type, By Source, By Indication (Cancer, Infectious Diseases, Autoimmune Disorders, and Others), By Manufacturing Modality, By End User, By Geography |
||||||
세포 면역 치료 시장은 2026년에 88억 1,000만 달러로 추정되며, 2033년까지 238억 6,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 15.3%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 88억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 15.30% | 2033년 시장 규모 예측 : | 238억 6,000만 달러 |
세계 세포 면역 치료 시장은 현대 의학에서 획기적인 패러다임의 전환을 나타내며, 특히 암과 자가면역 질환을 비롯한 다양한 질환과 싸우기 위해 인체 자체의 면역 체계를 활용하고 있습니다.
이 혁신적인 치료 접근법은 면역 세포를 채취하고 변형한 후 환자의 체내에 다시 주입함으로써, 선천적인 방어 기전을 강화합니다. 세포 면역 요법에는 CAR-T 세포 요법, 종양 침윤 림프구(TIL) 요법, 자연살해(NK) 세포 요법, 수지상 세포 백신 등 다양한 치료법이 포함되어 있으며, 각각은 특정 질환 경로를 표적으로 하는 독자적인 작용기전을 가지고 있습니다.
난치성 혈액암 치료에서 탁월한 효능을 입증한 Kymriah나 Yescarta와 같은 CAR-T 요법의 획기적인 승인을 계기로, 시장은 전례 없는 성장을 이루고 있습니다. 자동화된 세포 처리 시스템 및 밀폐형 바이오리액터와 같은 첨단 제조 기술 덕분에, 이러한 맞춤형 치료의 확장성과 표준화가 크게 향상되었습니다.
CRISPR-Cas9과 같은 유전자 편집 도구, 합성생물학 플랫폼, 인공지능(AI)을 활용한 환자 선별 알고리즘 등 생명공학 분야의 혁신이 융합됨에 따라, 세포 면역 요법의 치료 가능성은 계속해서 확대되고 있습니다. 전 세계 의료 시스템이 이러한 ‘생체 의약품’이 지닌 혁신적인 잠재력을 인식함에 따라, 연구 인프라, 규제 체계 및 보험 급여 정책에 대한 막대한 투자가 다양한 환자 집단에서 시장 확산과 접근성 향상을 가속화하고 있습니다.
시장 역학
세계 세포 면역 치료 시장은 몇 가지 강력한 요인의 견인 속에 견조한 성장을 이루고 있습니다. 그 주된 요인은 전 세계 암 유병률 증가이며, 특히 세포 면역 요법이 탁월한 임상 성과를 보이고 있는 혈액 악성 종양이 대표적입니다. 이 시장은 대형 제약사, 생명공학 기업 및 학술 기관의 연구 개발 활동에 대한 막대한 투자로 큰 혜택을 보고 있으며, 차세대 세포 공학 기술 분야의 혁신을 촉진하고, 치료 적용 분야를 종양학을 넘어 자가면역 질환, 감염증, 재생 의학으로 확대되고 있습니다.
규제 당국이 세포 면역 요법을 위한 신속 승인 절차를 마련하고, 획기적인 치료법(브레이크스루 테라피)으로 지정하며, 희귀질환 치료제(오펀 드럭)로 지정함으로써, 유망한 치료법 시장 출시 기간을 단축하고 지속적인 투자와 개발을 촉진하고 있습니다.
그러나 이 시장은 맞춤형 세포 치료에 수반되는 매우 높은 제조 비용, 전문 시설과 훈련된 인력이 필요한 복잡한 공급망 물류, 그리고 제품의 품질과 일관성을 유지하면서 생산 규모를 확대할 때 직면하는 중대한 기술적 과제 등 상당한 제약에 직면해 있습니다. 환자별로 맞춤형 치료제를 제조하는 데 수주가 소요되는 경우가 많은 긴 제조 기간 또한 운영상의 추가적인 과제를 야기하며, 중증 환자들의 치료 접근성을 제한하고 있습니다.
또한, 특정 세포 면역 요법에 수반되는 사이토카인 방출 증후군이나 신경 독성 등의 심각한 이상 반응을 대처하기 위해서는 전문적인 의료 인프라와 전문 지식이 필요하며, 이는 충분한 자원을 갖추지 못한 의료 기관에서의 도입을 제한하고 있습니다. 이러한 과제가 있음에도 불구하고, 현재의 혈액 질환 적응증보다 훨씬 더 많은 환자층을 차지하는 고형암으로의 적응증 확대와, 비용 및 제조의 복잡성을 획기적으로 줄이면서, 전 세계 시장 전반에서 치료 접근성과 확장성을 향상시킬 수 있는 기성(오프 더 셸프) 동종 세포 치료제의 개발을 통해, 이 시장에는 큰 기회가 존재합니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 주요 항목(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)을 바탕으로 전 세계 세포 면역 치료 시장의 주요 기업 프로파일을 작성하였습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계 세포 면역 요법 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 세포 면역 요법 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 세포 면역 치료 시장 : 요법 유형별, 2021년-2033년
제5장 세계의 세포 면역 치료 시장 : 소스별, 2021년-2033년
제6장 세계의 세포 면역 치료 시장 : 적응증별, 2021년-2033년
제7장 세계의 세포 면역 치료 시장 : 제조 방식별, 2021년-2033년
제8장 세계의 세포 면역 치료 시장 : 최종사용자별, 2021년-2033년
제9장 세계의 세포 면역 치료 시장 : 지역별, 2021년-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 조사 방법
LSHCellular Immunotherapy Market is estimated to be valued at USD 8.81 Bn in 2026 and is expected to reach USD 23.86 Bn by 2033, growing at a compound annual growth rate (CAGR) of 15.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.81 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 15.30% | 2033 Value Projection: | USD 23.86 Bn |
The global cellular immunotherapy market represents a revolutionary paradigm shift in modern medicine, leveraging the body's own immune system to combat various diseases, particularly cancer and autoimmune disorders.
This innovative therapeutic approach involves extracting, modifying, and reintroducing immune cells back into patients to enhance their natural defense mechanisms. Cellular immunotherapy encompasses diverse treatment modalities including CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, natural killer (NK) cell therapy, and dendritic cell vaccines, each offering unique mechanisms of action to target specific disease pathways.
The market has witnessed unprecedented growth following breakthrough approvals of CAR-T therapies such as Kymriah and Yescarta, which demonstrated remarkable efficacy in treating refractory hematologic malignancies. Advanced manufacturing technologies, including automated cell processing systems and closed-system bioreactors, have significantly improved the scalability and standardization of these personalized treatments.
The convergence of biotechnology innovations, including gene editing tools like CRISPR-Cas9, synthetic biology platforms, and artificial intelligence-driven patient selection algorithms, continues to expand the therapeutic potential of cellular immunotherapies. As healthcare systems globally recognize the transformative potential of these living medicines, substantial investments in research infrastructure, regulatory frameworks, and reimbursement policies are accelerating market adoption and accessibility across diverse patient populations.
Market Dynamics
The global cellular immunotherapy market experiences robust growth driven by several compelling factors, with the primary driver being the increasing prevalence of cancer worldwide, particularly hematologic malignancies where cellular immunotherapies have demonstrated exceptional clinical outcomes. The market benefits significantly from substantial investments in research and development activities by pharmaceutical giants, biotechnology companies, and academic institutions, fostering innovation in next-generation cell engineering technologies and expanding therapeutic applications beyond oncology into autoimmune diseases, infectious diseases, and regenerative medicine.
Regulatory agencies' establishment of expedited approval pathways, breakthrough therapy designations, and orphan drug status for cellular immunotherapies has accelerated time-to-market for promising treatments, encouraging continued investment and development.
However, the market faces considerable restraints including extremely high manufacturing costs associated with personalized cell processing, complex supply chain logistics requiring specialized facilities and trained personnel, and significant technical challenges in scaling production while maintaining product quality and consistency. Lengthy manufacturing timelines, often requiring weeks to produce patient-specific treatments, pose additional operational challenges and limit treatment accessibility for critically ill patients.
Furthermore, severe adverse events such as cytokine release syndrome and neurotoxicity associated with certain cellular immunotherapies necessitate specialized medical infrastructure and expertise, constraining adoption in healthcare facilities lacking adequate resources. Despite these challenges, the market presents substantial opportunities through expanding applications into solid tumors, which represent a significantly larger patient population than current hematologic indications, and the development of off-the-shelf allogeneic cell therapies that could dramatically reduce costs and manufacturing complexity while improving treatment accessibility and scalability across global markets.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cellular immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Gilead Sciences Inc (Kite Pharma), Bristol Myers Squibb Company, Johnson and Johnson (Janssen Biotech), Cellectis S.A., Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Allogene Therapeutics Inc, Atara Biotherapeutics Inc, Legend Biotech Corporation, bluebird bio Inc, Fate Therapeutics Inc, ImmunityBio Inc, Iovance Biotherapeutics Inc, and Poseida Therapeutics Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cellular immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cellular immunotherapy market
Market Segmentation
- Therapy Type Insights (Revenue, USD Bn, 2021 - 2033)
- CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
- TCR-T Cell Therapy (T-Cell Receptor T-cell)
- NK Cell Therapy (Natural Killer cell therapy)
- Dendritic Cell Therapy
- Tumor-Infiltrating Lymphocytes (TIL) Therapy
- Macrophage-Based Cell Therapy
- Others (emerging/novel cell types)
- Source Insights (Revenue, USD Bn, 2021 - 2033)
- Autologous (patient-derived cells)
- Allogeneic (donor-derived cells)
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Cancer
- Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
- Infectious Diseases
- Bacterial Infections (e.g., tuberculosis)
- Autoimmune Disorders
- Multiple Sclerosis
- Rheumatoid Arthritis
- Type 1 Diabetes
- Others
- Manufacturing Modality Insights (Revenue, USD Bn, 2021 - 2033)
- Ex Vivo Cell Expansion
- In Vivo Engineering
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Clinics
- Specialty Endocrinology and Obesity Centers
- Ambulatory Surgical Centers (ASCs)
- Home Healthcare Services
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Gilead Sciences Inc (Kite Pharma)
- Bristol Myers Squibb Company
- Johnson and Johnson (Janssen Biotech)
- Cellectis S.A.
- Adaptimmune Therapeutics plc
- Autolus Therapeutics plc
- Allogene Therapeutics Inc
- Atara Biotherapeutics Inc
- Legend Biotech Corporation
- bluebird bio Inc
- Fate Therapeutics Inc
- ImmunityBio Inc
- Iovance Biotherapeutics Inc
- Poseida Therapeutics Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cellular Immunotherapy Market, By Therapy Type
- Global Cellular Immunotherapy Market, By Source
- Global Cellular Immunotherapy Market, By Indication
- Global Cellular Immunotherapy Market, By Manufacturing Modality
- Global Cellular Immunotherapy Market, By End User
- Global Cellular Immunotherapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Cellular Immunotherapy Market, By Therapy Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- TCR-T Cell Therapy (T-Cell Receptor T-cell)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- NK Cell Therapy (Natural Killer cell therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Dendritic Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Tumor-Infiltrating Lymphocytes (TIL) Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Macrophage-Based Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (emerging/novel cell types)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Cellular Immunotherapy Market, By Source, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Autologous (patient-derived cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Allogeneic (donor-derived cells)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Cellular Immunotherapy Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)
- Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bacterial Infections (e.g., tuberculosis)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Multiple Sclerosis
- Rheumatoid Arthritis
- Type 1 Diabetes
- Multiple Sclerosis
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Cellular Immunotherapy Market, By Manufacturing Modality, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Ex Vivo Cell Expansion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- In Vivo Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Cellular Immunotherapy Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Endocrinology and Obesity Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Healthcare Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Cellular Immunotherapy Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Source, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Modality, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc (Kite Pharma)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson (Janssen Biotech)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cellectis S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Adaptimmune Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Autolus Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allogene Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Atara Biotherapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Legend Biotech Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- bluebird bio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fate Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ImmunityBio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Iovance Biotherapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Poseida Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
